Walmart Expands Autoimmune-Focused Care to 25 More Pharmacies Across Five States

July 25, 2024

Arcutis Submits sNDA to FDA for ZORYVE Foam 0.3% for Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Older

July 23, 2024

Scinai’s Intralesional Anti-IL-17 NanoAb Shows Early Promise in Mild to Moderate PsO

July 15, 2024

Inside Sun Pharma’s I LUV YA for The Long Haul PsO Campaign

July 13, 2024

Risankizumab Bests Other Biologics in Real-world Psoriasis Study

July 2, 2024

Will Blocking FABP5 Help Treat Psoriasis?

July 2, 2024

Real-world Data: Tildrakizumab Restores and Maintains Wellbeing of PsO Patients

June 28, 2024

Japan Approves Dermavant’s Tapinarof Cream in PsO and AD

June 25, 2024

What Is Well-being in Psoriasis?

June 24, 2024

Spotlight on Psychodermatology: Yale Study Links PsO to OCD

June 19, 2024

EULAR News: IL-12/23 and IL-23 Blockers May Prevent Progression to PsA in PsO Patients

June 12, 2024

MoonLake Immunotherapeutics Receives Regulatory Greenlights for Phase 3 Program of Sonelokimab in PsA

June 10, 2024